Table 4.
The distribution of anti-Dtx, anti-Ttx and anti-Ptx IgG in neonates hospitalized in the neonatal ward
| Antibody level | N, Prevalence (95% CI) | χ2, P | |||
|---|---|---|---|---|---|
| Shunyi | Qianjiang | ||||
| Anti-Dtx IgG | |||||
| < 0.01 IU/ml | 5 | 2.5% (1.1–5.7%) | 102 | 42.9% (36.7–49.2%) | χ2 = 95.876, P < 0.0001 |
| 0.01- < 0.1 IU/ml | 134 | 67.0% (60.2–73.1%) | 119 | 50.0% (43.7–56.3%) | χ2 = 12.873, P = 0.0003 |
| 0.1–1.0 IU/ml | 60 | 30.0% (24.1–36.7%) | 16 | 6.72% (4.2–10.6%) | χ2 = 41.016, P < 0.0001 |
| > 1.0–1.5 IU/ml | 0 | 0 (0–1.9%) | 0 | 0 (0–1.6%) | – |
| > 1.5–2.0 IU/ml | 0 | 0 (0–1.9%) | 1 | 0.4% (0.1–2.3%) | χ2 = 0.842, P = 0.3588 |
| > 2.0 IU/ml | 1 | 0.5% (0.1–2.8%) | 0 | 0 (0–1.6%) | χ2 = 1.193, P = 0.2748 |
| Anti-Ttx IgG | |||||
| < 0.01 IU/ml | 58 | 29.0% (23.2–35.6%) | 105 | 44.2% (38.0–50.5%) | χ2 = 10.63, P = 0.0011 |
| 0.01–0.1 IU/ml | 85 | 42.5% (35.9–49.4%) | 115 | 48.3% (42.1–54.6%) | χ2 = 1.483, P = 0.2233 |
| > 0.1–0.5 IU/ml | 36 | 18.0% (13.3–23.9%) | 17 | 7.1% (4.5–11.1%) | χ2 = 12.044, P = 0.0005 |
| > 0.5–1.0 IU/ml | 16 | 8.0% (5.0–12.6%) | 1 | 0.4% (0.1–2.3%) | χ2 = 16.737, P < 0.0001 |
| > 1.0–5.0 IU/ml | 4 | 2.0% (0.8–5.0%) | 0 | 0 (0–1.6%) | χ2 = 4.804, P = 0.0284 |
| > 5.0 IU/ml | 1 | 0.5% (0.1–2.8%) | 0 | 0 (0–1.6%) | χ2 = 1.193, P = 0.2748 |
| Anti-Ptx IgG | |||||
| < 5.0 IU/ml | 139 | 69.5% (62.8–75.5%) | 143 | 60.1% (53.8–66.1%) | χ2 = 4.202, P = 0.0404 |
| 5.0- < 40.0 IU/ml | 59 | 29.5% (23.6–36.2%) | 90 | 37.8% (31.9–44.1%) | χ2 = 3.348, P = 0.0673 |
| 40.0- < 100.0 IU/ml | 2 | 1.0% (0.3–3.6%) | 3 | 1.3% (0.4–3.6%) | χ2 = 0.065, P = 0.7982 |
| ≥ 100.0 IU/ml | 0 | 0 (0–1.9%) | 2 | 0.8% (0.2–3.0%) | χ2 = 1.688, P = 0.1932 |